Battiloro E, Ombres D, Pascale E, D'Ambrosio E, Verna R, Arca M
Cattedra di Patologia Clinica, Dipartimento di Medicina Sperimentale e Patologia, Università di Roma La Sapienza, Rome, Italy.
Eur J Hum Genet. 2000 May;8(5):389-92. doi: 10.1038/sj.ejhg.5200465.
The identification of mutations in the haemochromatosis gene (HFE) (C282Y and H63D) provides the unique opportunity to test whether genetic variants that are associated with tissue iron accumulation may influence the risk of coronary atherosclerosis. To this aim the prevalence of C282Y and H63D mutations was determined in 174 patients with angiographically documented CAD (>50% stenosis) and history of MI, 187 healthy free-living individuals and 142 blood donors. C282Y and H63D mutations were not found to be more frequent in coronary patients as compared to controls. Moreover, these HFE variants were unrelated to the severity of coronary atherosclerosis. These findings did not provide evidence of an association between HFE mutations and the presence of coronary atherosclerosis or its major ischaemic complications, thus indicating that HFE mutations are poor genetic markers of coronary risk.
血色素沉着病基因(HFE)(C282Y和H63D)突变的鉴定提供了一个独特的机会,来测试与组织铁蓄积相关的基因变异是否会影响冠状动脉粥样硬化的风险。为此,在174例经血管造影证实患有CAD(狭窄>50%)且有心肌梗死病史的患者、187名健康自由生活个体和142名献血者中,测定了C282Y和H63D突变的发生率。与对照组相比,未发现C282Y和H63D突变在冠心病患者中更常见。此外,这些HFE变异与冠状动脉粥样硬化的严重程度无关。这些发现没有提供HFE突变与冠状动脉粥样硬化的存在或其主要缺血性并发症之间存在关联的证据,因此表明HFE突变是冠状动脉风险的不良遗传标志物。